Drugs For Benign Prostatic hypertrophy Global Market Report 2025

Description

Benign prostatic hypertrophy drugs are used to treat enlarged prostate glands by relaxing the muscles in the bladder neck and the muscle fibers in the prostate, thereby facilitating easier urination. Benign prostatic hypertrophy is a condition commonly observed in men over the age of 50.

The primary categories of drugs used for benign prostatic hypertrophy include alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and other medications. Alpha-blockers, also known as blockers or adrenoreceptor antagonists, are a type of pharmaceutical drug that functions by blocking adrenergic receptors. These drugs are used in various sectors, including hospital pharmacies, retail pharmacies, and others, and they are distributed through a range of channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The drugs for benign prostatic hypertrophy market research report is one of a series of new reports from The Business Research Company that provides drugs for benign prostatic hypertrophy market statistics, including drugs for benign prostatic hypertrophy industry global market size, regional shares, competitors with drugs for benign prostatic hypertrophy market share, detailed drugs for benign prostatic hypertrophy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for benign prostatic hypertrophy industry. This drugs for benign prostatic hypertrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drugs for benign prostatic hypertrophy market size has grown strongly in recent years. It will grow from $4.28 billion in 2024 to $4.58 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to aging population, increased awareness, advancements in drug therapies, healthcare access.

The drugs for benign prostatic hypertrophy market size is expected to see strong growth in the next few years. It will grow to $5.58 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to emerging markets, new drug developments, increasing awareness and education, regulatory approvals. Major trends in the forecast period include minimally invasive treatments, personalized medicine, combination therapies, patient-centered care, telemedicine and digital health, research and development.

The global growth in the male geriatric population is a key driver of the drugs for benign prostatic hypertrophy market since this condition is commonly observed in men aged 50 and above. As an example, in October 2022, the World Health Organization, a US-based specialized health agency, reported that by 2030, an estimated 1 in 6 individuals globally would be 60 years or older, and this figure is projected to increase to 2.1 billion elderly individuals by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia (BPH) affects approximately 50% of men aged between 51 and 60 years, and this percentage rises to as high as 90% among men aged over 80 years.

The growth of the drugs for benign prostatic hypertrophy (BPH) market is expected to be driven by the increasing prevalence of prostate diseases. Prostate diseases encompass a range of medical conditions affecting the prostate gland, a male reproductive organ located just below the bladder. Drugs for BPH play a crucial role in managing and alleviating urinary symptoms related to prostate conditions, offering relief by reducing prostate enlargement and improving urine flow. For instance, in June 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, there were 236,659 new cases of prostate cancer reported in the United States in 2021, with 33,363 men succumbing to the disease in 2022. Therefore, the rising incidence of prostate diseases is driving the growth of the BPH drug market.

Major companies operating in the drugs for benign prostatic hypertrophy (BPH) market are focusing on developing innovative products, such as Polish drugs, to effectively support patients with urological diseases. Polish drugs are pharmaceutical products developed to diagnose, treat, prevent, or alleviate symptoms of various diseases and conditions, regulated by relevant health authorities to ensure safety, efficacy, and quality. For instance, in June 2023, Adamed Sp. z o.o., a Poland-based pharmaceutical company, launched a combination drug containing solifenacin succinate and tamsulosin hydrochloride. This fixed-dose medication effectively addresses lower urinary tract symptoms (LUTS) associated with BPH by reducing bladder contractions through solifenacin and facilitating urination with tamsulosin. The combination improves patient outcomes when compared to tamsulosin monotherapy.

Major companies operating in the drugs for benign prostatic hypertrophy (BPH) market are focusing on technological advancements, such as developing new medications that address both enlarged prostate (BPH) and erectile dysfunction (ED), to gain a competitive edge. BPH refers to the non-cancerous enlargement of the prostate gland, while ED is the inability to achieve or maintain an erection sufficient for sexual activity. For instance, in September 2023, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical contract manufacturer, launched the Tamsulosin + Tadalafil Capsule, expanding its product offerings in the men's health sector. This innovative product, branded Cromax, combines Tamsulosin, which targets smooth muscle relaxation in the prostate and urethra to improve urine flow, with Tadalafil, which enhances blood flow to the penis to facilitate erections. This dual-action formulation provides a convenient treatment option for men suffering from both BPH and ED, while also demonstrating significant improvements in the International Prostate Symptom Score (IPSS).

Major companies operating in the drugs for benign prostatic hypertrophy market include Allergan Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Limited, Sanofi S.A., Nymox Pharmaceutical Corporation, AEterna Zentaris Inc., Pfizer Inc., IntelGenx Technologies Corp., Ipsen S.A., Novartis International AG, Antibe Therapeutics Inc., Bausch Health Companies Inc., Bayer AG, Quest PharmaTech Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Impax Laboratories Inc., GemVax & KAEL Inc., Merck & Co. Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Allium Medical Solutions Ltd., Asahi Kasei Corporation, Asclepion Laser Technologies GmbH, Boston Scientific Corporation, Biolitec AG, Coloplast A/S, Eli Lilly and Company, Endo International PLC, IPG Photonics Corporation, KARL STORZ SE & Co. KG, LISA Laser Products AG, Medifocus Inc., Olympus Corporation, Pharex Health Corporation, PNN Medical A/S, Quanta S.p.A.

North America was the largest region in the drugs for benign prostatic hypertrophy market in 2024. Middle East is expected to be the fastest-growing region in the drugs for benign prostatic hypertrophy market. The regions covered in the drugs for benign prostatic hypertrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the drugs for benign prostatic hypertrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The drugs for benign postratic hypertrophy market consists of sales of alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drugs For Benign Prostatic hypertrophy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drugs for benign prostatic hypertrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drugs for benign prostatic hypertrophy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The drugs for benign prostatic hypertrophy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Alpha Blocker; 5-alpha Reductase Inhibitor; Phosphodiesterase-5 Inhibitor; Other Types
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Hospital Pharmacies; Retail Pharmacies; Other End-Users
Subsegments:
1) By Alpha Blocker: Tamsulosin; Alfuzosin; Doxazosin; Terazosin; Silodosin
2) By 5-alpha Reductase Inhibitor: Finasteride; Dutasteride
3) By Phosphodiesterase-5 Inhibitor: Tadalafil; Sildenafil
4) By Other Types: Anticholinergics; Herbal Supplements (Saw Palmetto); Combination Therapy Drugs (Alpha Blocker + 5-alpha Reductase Inhibitor)
Companies Mentioned: Allergan Inc.; Astellas Pharma Inc.; Boehringer Ingelheim International GmbH; GlaxoSmithKline plc; Teva Pharmaceutical Industries Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r32503

1. Executive Summary

2. Drugs For Benign Prostatic hypertrophy Market Characteristics

3. Drugs For Benign Prostatic hypertrophy Market Trends And Strategies

4. Drugs For Benign Prostatic hypertrophy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Drugs For Benign Prostatic hypertrophy Growth Analysis And Strategic Analysis Framework

5.1. Global Drugs For Benign Prostatic hypertrophy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Drugs For Benign Prostatic hypertrophy Market Growth Rate Analysis
5.4. Global Drugs For Benign Prostatic hypertrophy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Drugs For Benign Prostatic hypertrophy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Drugs For Benign Prostatic hypertrophy Total Addressable Market (TAM)

6. Drugs For Benign Prostatic hypertrophy Market Segmentation

6.1. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Alpha Blocker
5-alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Other Types
6.2. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.3. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Other End-Users
6.4. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Alpha Blocker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tamsulosin
Alfuzosin
Doxazosin
Terazosin
Silodosin
6.5. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of 5-alpha Reductase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Finasteride
Dutasteride
6.6. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Phosphodiesterase-5 Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tadalafil
Sildenafil
6.7. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anticholinergics
Herbal Supplements (Saw Palmetto)
Combination Therapy Drugs (Alpha Blocker + 5-alpha Reductase Inhibitor)

7. Drugs For Benign Prostatic hypertrophy Market Regional And Country Analysis

7.1. Global Drugs For Benign Prostatic hypertrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Drugs For Benign Prostatic hypertrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market

8.1. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Drugs For Benign Prostatic hypertrophy Market

9.1. China Drugs For Benign Prostatic hypertrophy Market Overview
9.2. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Drugs For Benign Prostatic hypertrophy Market

10.1. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Drugs For Benign Prostatic hypertrophy Market

11.1. Japan Drugs For Benign Prostatic hypertrophy Market Overview
11.2. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Drugs For Benign Prostatic hypertrophy Market

12.1. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Drugs For Benign Prostatic hypertrophy Market

13.1. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Drugs For Benign Prostatic hypertrophy Market

14.1. South Korea Drugs For Benign Prostatic hypertrophy Market Overview
14.2. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Drugs For Benign Prostatic hypertrophy Market

15.1. Western Europe Drugs For Benign Prostatic hypertrophy Market Overview
15.2. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Drugs For Benign Prostatic hypertrophy Market

16.1. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Drugs For Benign Prostatic hypertrophy Market

17.1. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Drugs For Benign Prostatic hypertrophy Market

18.1. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Drugs For Benign Prostatic hypertrophy Market

19.1. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Drugs For Benign Prostatic hypertrophy Market

20.1. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Drugs For Benign Prostatic hypertrophy Market

21.1. Eastern Europe Drugs For Benign Prostatic hypertrophy Market Overview
21.2. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Drugs For Benign Prostatic hypertrophy Market

22.1. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Drugs For Benign Prostatic hypertrophy Market

23.1. North America Drugs For Benign Prostatic hypertrophy Market Overview
23.2. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Drugs For Benign Prostatic hypertrophy Market

24.1. USA Drugs For Benign Prostatic hypertrophy Market Overview
24.2. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Drugs For Benign Prostatic hypertrophy Market

25.1. Canada Drugs For Benign Prostatic hypertrophy Market Overview
25.2. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Drugs For Benign Prostatic hypertrophy Market

26.1. South America Drugs For Benign Prostatic hypertrophy Market Overview
26.2. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Drugs For Benign Prostatic hypertrophy Market

27.1. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Drugs For Benign Prostatic hypertrophy Market

28.1. Middle East Drugs For Benign Prostatic hypertrophy Market Overview
28.2. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Drugs For Benign Prostatic hypertrophy Market

29.1. Africa Drugs For Benign Prostatic hypertrophy Market Overview
29.2. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape And Company Profiles

30.1. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape
30.2. Drugs For Benign Prostatic hypertrophy Market Company Profiles
- 30.2.1. Allergan Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Teva Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis

31. Drugs For Benign Prostatic hypertrophy Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. Nymox Pharmaceutical Corporation
31.3. AEterna Zentaris Inc.
31.4. Pfizer Inc.
31.5. IntelGenx Technologies Corp.
31.6. Ipsen S.A.
31.7. Novartis International AG
31.8. Antibe Therapeutics Inc.
31.9. Bausch Health Companies Inc.
31.10. Bayer AG
31.11. Quest PharmaTech Inc.
31.12. Bristol-Myers Squibb Company
31.13. Endo Pharmaceuticals Inc.
31.14. Kaken Pharmaceutical Co. Ltd.
31.15. Impax Laboratories Inc.

32. Global Drugs For Benign Prostatic hypertrophy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Drugs For Benign Prostatic hypertrophy Market

34. Recent Developments In The Drugs For Benign Prostatic hypertrophy Market

35. Drugs For Benign Prostatic hypertrophy Market High Potential Countries, Segments and Strategies

35.1 Drugs For Benign Prostatic hypertrophy Market In 2029 - Countries Offering Most New Opportunities
35.2 Drugs For Benign Prostatic hypertrophy Market In 2029 - Segments Offering Most New Opportunities
35.3 Drugs For Benign Prostatic hypertrophy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer